Indian pharmaceutical manufacturers expanded their position in China’s tightly regulated drug market this year, securing several high-volume supply contracts under the country’s volume-based procurement (VBP) program. Hetero Labs, Cipla, Annora Pharma, and Natco Pharma won bids for seven products—including the high-demand diabetes therapy dapagliflozin—according to the India–China Economic and Cultural Council (ICEC). These wins affirm … Indian Generics Gain Ground in China as the Global Procurement Landscape Demands a New Industrial Model Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.